Human Cytomegalovirus UL7, miR-US5-1, and miR-UL112-3p Inactivation of FOXO3a Protects CD34+ Hematopoietic Progenitor

Meaghan H Hancock1, Lindsey B Crawford1, Wilma Perez1

  • 1Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, Oregon, USA.

Msphere
|January 7, 2021
PubMed

Insights

Human cytomegalovirus (HCMV) infection uses viral protein pUL7 and microRNAs (miRNAs) to block apoptosis in hematopoietic progenitor cells (HPCs). This prevents cell death, aiding HCMV latency establishment in HPCs.

Area of Science:

  • Virology
  • Immunology
  • Cell Biology

Background:

  • Human cytomegalovirus (HCMV) establishes latency in CD34+ hematopoietic progenitor cells (HPCs).
  • Mechanisms by which HCMV regulates apoptosis in infected HPCs are not fully understood.
  • HCMV infection upregulates antiapoptotic proteins, but proapoptotic protein regulation needs further exploration.

Purpose of the Study:

  • To investigate the mechanisms HCMV uses to regulate proapoptotic proteins in CD34+ HPCs.
  • To identify viral factors involved in preventing apoptosis during early HCMV infection of HPCs.
  • To understand how these viral factors contribute to HCMV latency.

Main Methods:

  • Analysis of HCMV-infected CD34+ HPCs.
  • Investigation of the roles of viral protein pUL7 and microRNAs (miRNAs) miR-US5-1 and miR-UL112-3p.
  • Assessment of the impact on the proapoptotic transcription factor FOXO3a and its downstream targets.

Main Results:

  • HCMV utilizes viral protein pUL7 and miRNAs miR-US5-1 and miR-UL112-3p to reduce FOXO3a abundance and activity.
  • This viral regulation leads to decreased expression of the proapoptotic BCL2L11 transcript.
  • HCMV-induced apoptosis in CD34+ HPCs is prevented, facilitating viral latency.

Conclusions:

  • Both viral proteins and miRNAs are crucial for protecting CD34+ HPCs from apoptosis early in HCMV infection.
  • The pUL7, miR-US5-1, and miR-UL112-3p pathway targeting FOXO3a is essential for HCMV latency.
  • Understanding these mechanisms is vital for addressing HCMV-related diseases in immunocompromised individuals.